Not admitted · Not a forecast

Part I of the MDMA-AT series, 'Submitted data' section, discussing Breakthrough Status and the FDA's acceptance of the Lykos New Drug Application. The author states as a general point that FDA acceptance of an NDA for review does not mean the agency thinks it is a good idea, nor that it is likely to approve it.

Descriptive, retrospective, or a statement of preference; no future state asserted.